Castle biosciences to release second quarter 2019 financial results and host conference call on tuesday, september 3, 2019
Friendswood, texas--(business wire)--castle biosciences, inc. (nasdaq: cstl) today announced that it will release its financial results for the second quarter ended june 30, 2019 after the close of market on tuesday, september 3, 2019. company management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. eastern time on the same day. conference call details the conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/tk8ypudk. please access the webcast at least 10 minutes before the conference call start time. to access the live conference call via phone, please dial 877-282-2581 from the united states and canada, or +1 470-495-9479 internationally, at least 10 minutes prior to the start of the call, using the conference id 2368125. a replay of the webcast will be available for two weeks following the conclusion of the live broadcast and will be accessible on the company’s website at www.castlebiosciences.com from the “investors” page. about castle biosciences castle biosciences (nasdaq: cstl) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. the company currently offers tests for patients with cutaneous melanoma (decisiondx®-melanoma, decisiondx®-cmseq; www.skinmelanoma.com) and uveal melanoma (decisiondx®-um, decisiondx®-prame and decisiondx®-umseq; www.myuvealmelanoma.com), with products in development for other underserved cancers, the two most advanced of which are focused on patients with cutaneous squamous cell carcinoma, and patients who have a difficult-to-diagnose pigmented lesion. castle biosciences is based in friendswood, texas (houston), and has laboratory operations in phoenix, arizona. for more information, visit www.castlebiosciences.com. decisiondx-melanoma, decisiondx-cmseq, decisiondx-um, decisiondx-prame and decisiondx-umseq are the trademarks of castle biosciences, inc.
CSTL Ratings Summary
CSTL Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission